Establishing secure connection…Loading editor…Preparing document…

Mutual Partnership MNDA

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

MUTUAL PARTNERSHIP MNDA

This Mutual Nondisclosure Agreement ("Agreement") is entered into as of Effective Date: by and between Party A: with principal address , and Party B: with principal address (each a "Party" and collectively the "Parties").

RECITALS

WHEREAS, the Parties anticipate discussions and potential collaboration relating to a business partnership opportunity described as: (the "Purpose"); and

WHEREAS, in connection with the Purpose, each Party may disclose to the other certain confidential and proprietary information that the disclosing Party desires to protect; and

WHEREAS, the Parties wish to define their rights and obligations with respect to the confidentiality of such information.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows:

1. DEFINITIONS

"Confidential Information" means all nonpublic information disclosed, whether disclosed orally, visually or in writing, or by inspection of tangible objects, including without limitation business plans, financial information, customer and supplier lists, product roadmaps, technical data, designs, trade secrets and know-how, whether or not marked or identified as confidential.

2. OBLIGATIONS OF THE PARTIES

Each Party receiving Confidential Information (the "Recipient") shall: (a) hold such information in strict confidence and not disclose it to any third party except as expressly permitted by this Agreement; (b) restrict disclosure to its employees, agents or affiliates having a need to know and who are bound by confidentiality obligations at least as protective as those herein; and (c) use the Confidential Information solely for the Purpose.

3. EXCLUSIONS

Confidential Information does not include information that the Recipient can demonstrate by written evidence: (a) was known to the Recipient prior to disclosure by the Discloser without restriction; (b) is or becomes generally available to the public through no wrongful act of the Recipient; (c) is rightfully received from a third party without restriction and without breach of any obligation of confidentiality; or (d) is independently developed by the Recipient without use of or reference to the Discloser's Confidential Information.

4. REQUIRED DISCLOSURE

If the Recipient is required by law, regulation or court order to disclose Confidential Information, the Recipient shall (to the extent legally permitted) provide prompt written notice to the Discloser and cooperate reasonably in seeking protective measures or confidential treatment. The Recipient will disclose only that portion legally required and will use reasonable efforts to obtain confidential treatment.

5. TERM; RETURN OR DESTRUCTION

This Agreement shall commence on the Effective Date and continue for a period of years unless earlier terminated by mutual written agreement. Notwithstanding expiration or termination, the Recipient's obligations with respect to Confidential Information shall survive for a period of years from the date of disclosure or for as long as the information remains a trade secret under applicable law, whichever is longer.

Upon termination or at the Discloser's written request, the Recipient shall promptly return or destroy all written materials embodying Confidential Information and certify in writing that it has complied with this obligation, except that Recipient may retain one archival copy in its legal files subject to the confidentiality obligations of this Agreement.

6. INTELLECTUAL PROPERTY; NO LICENSE

All Confidential Information and any derivatives remain the property of the Discloser. Except for the limited right to use Confidential Information for the Purpose, no license, express or implied, is granted by either Party under any patent, trademark, copyright, trade secret or other intellectual property right.

7. REMEDIES

The Parties acknowledge that monetary damages may be inadequate to protect the Discloser against breach of this Agreement. Accordingly, in addition to any other remedies available at law or in equity, the Discloser shall be entitled to seek injunctive relief and specific performance without posting bond. Nothing in this Section shall limit the Discloser's right to pursue any other remedies.

8. LIMITATION OF LIABILITY

Except for breaches of confidentiality, willful misconduct or gross negligence, neither Party shall be liable to the other for indirect, incidental, consequential, special or punitive damages arising out of this Agreement, even if advised of the possibility of such damages.

9. NOTICES

10. AMENDMENTS; WAIVER

No amendment, modification or waiver of any provision of this Agreement shall be effective unless in writing and signed by authorized representatives of both Parties. A waiver by either Party of a breach shall not operate as a waiver of any other breach.

11. COUNTERPARTS

This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Signatures transmitted by electronic means shall be binding.

12. SEVERABILITY

If any provision of this Agreement is held invalid or unenforceable, the remaining provisions shall remain in full force and effect and the Parties shall negotiate in good faith a substitute provision to carry out the original intent.

13. GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the jurisdiction selected by the Parties: without regard to choice of law principles that would result in the application of the laws of another jurisdiction.

14. ENTIRE AGREEMENT

This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, proposals and communications, whether oral or written, relating to such subject matter.

ADDITIONAL PROVISIONS

REPRESENTATIONS

Each Party represents and warrants that it has the full right, power and authority to enter into this Agreement and to grant the rights and assume the obligations herein. Each Party further represents that execution of this Agreement will not violate any other agreement to which it is a party.

ENTITY TYPE

Party A Entity Type:

Party B Entity Type:

SIGNATURES

Party A:

By:

Date:

Party B:

By:

Date:

Enter text✕

What the Mutual Partnership MNDA Is and When It Applies

The Mutual Partnership MNDA is a bilateral non-disclosure agreement used when two parties evaluate or pursue a collaborative business relationship and need reciprocal protection for confidential information. It defines confidential material, permitted uses, obligations to safeguard information, exclusions such as public domain or independently developed data, and procedures for return or destruction. Typical clauses address term and survival, permitted disclosures to advisors, remedies for breach, and governing law. The agreement is suited to exploratory meetings, joint pilots, due diligence, and information exchange during vendor or product partnerships.

Why organizations rely on a Mutual Partnership MNDA

A Mutual Partnership MNDA creates clear, reciprocal obligations that protect trade secrets, technical data, and business plans while enabling candid information exchange during partnership evaluation.

Why organizations rely on a Mutual Partnership MNDA

Who typically completes a Mutual Partnership MNDA

Parties involved in exploratory commercial or technical partnerships commonly use a mutual NDA to permit simultaneous disclosure while limiting downstream use.

  • Corporate legal teams and in-house counsel managing clause language and risk allocation during negotiations.
  • Business development and partnerships teams coordinating information exchange and aligning scope with commercial objectives.
  • Product and engineering leads supplying technical details and ensuring technical exclusions and security controls are addressed.

Use this section to identify the internal roles and external counterparties who should review, approve, and sign the agreement.

Primary signers and approvers

Chief Legal Officer

Typically reviews and approves final MNDA language, confirms liability caps and remedy provisions, and signs for the company when delegated authority requires senior-level approval.

Business Development Lead

Coordinates information exchange, identifies the business purpose, confirms permitted recipients, and often signs or countersigns when the internal approval threshold is lower.

Step-by-step: filling and finalizing the MNDA

Follow a clear sequence to prepare, review, sign, and record the Mutual Partnership MNDA to reduce negotiation cycles and execution risk.

  • 01
    Prepare: Populate parties, purpose, and confidential definition.
  • 02
    Review: Legal and business teams confirm scope and obligations.
  • 03
    Sign: Execute by authorized signatories and date the signature.
  • 04
    Record: Store the fully executed agreement and audit trail.

Typical MNDA circulation and approval flow

A predictable circulation model speeds execution and maintains a clear audit trail for each disclosure event.

  • Originator: Drafts initial MNDA and populates key fields.
  • Internal Review: Legal and security teams validate clauses and security controls.
  • External Review: Counterparty reviews and proposes redlines if needed.
  • Execution: Authorized signers execute and exchange fully signed copies.

Key provisions to include in a professional Mutual Partnership MNDA

Cover these provisions to make the agreement clear, enforceable, and fit for partnership evaluation while limiting downstream liability.

Mutual Obligations

Reciprocal duties to protect disclosed information, including standard of care and obligation to notify on breach; clearly allocate responsibilities between parties.

Definition of Confidentiality

Precise categories of protected data and excluded items such as independently developed or public-domain information.

Permitted Use

Limit use to the stated business purpose and prohibit reverse engineering, resale, or unauthorized disclosure to third parties.

Term and Survival

Set an express confidentiality term and list survival for trade secrets and other clauses that must outlast termination.

Remedies

Include injunctive relief language, damages allocation, and interim remedies to address irreparable harm.

Return and Destruction

Procedures for returning or destroying confidential materials and certification of compliance upon request.

Security and compliance checkpoints to reference

Encryption: TLS 1.2/1.3; AES-256 at rest
Audit Trail: Timestamps, IP, and action log
Access Controls: Role-based permissions
HIPAA BAA: BAA available if PHI involved
Retention Policy: Defined document lifecycle
Certifications: SOC 2 Type II; ISO 27001

Key risks and consequences of an incorrect MNDA

Civil Liability: Damages for breach
Injunctive Relief: Court-ordered stop to disclosures
Contract Termination: Loss of partnership opportunities
Regulatory Fines: HIPAA penalties if PHI mishandled
Reputational Harm: Loss of client trust
Operational Delay: Negotiation cycles and redlines

Common preparation mistakes to avoid

  • Using an overly broad definition of confidential information that captures routine public materials and invites disputes.
  • Failing to identify permitted recipients and leaving open unlimited subcontractor disclosures without controls.
  • Neglecting to specify the effective date or survival period, which creates ambiguity for enforcement and statute limitations.
  • Skipping internal signatory authority checks, causing later invalidation when an unauthorized employee executed the agreement.

Configuring an online MNDA workflow for efficient execution

Set up a digital workflow that enforces signer order, collects authentication, and captures an auditable completion certificate.

Field Configuration
Signer Order Simultaneous or sequential signing
Authentication Email link, SMS code, or KBA
Conditional Fields Show fields only when applicable
Audit Options Retain IP, timestamp, and audit trail

Digital signing and integration considerations

Choose a signing platform that captures a complete audit trail and supports your required authentication level.

  • Integrations: Salesforce, NetSuite, Google Workspace
  • Formats: PDF, DOCX, HTML supported
  • Authentication: Email, SMS, or stronger methods

Typical eSignature pricing and capability snapshot for executing a Mutual Partnership MNDA

Basic pricing and feature availability vary by vendor; compare starting price, trial availability, bulk send, audit trail, HIPAA support, and envelope limits.

signNow DocuSign Adobe Sign PandaDoc HelloSign
Starting Price $8/user/mo $15/user/mo $14/user/mo $19/user/mo $15/user/mo
Free Trial 7-day free trial Varies by vendor Varies by vendor Varies by vendor Varies by vendor
Bulk Send Yes (Business Premium) Yes Yes Yes No
Audit Trail Yes Yes Yes Yes Yes
HIPAA Compliant Yes Yes Yes No No

FAQs — practical answers for the Mutual Partnership MNDA

Common questions focus on enforceability, e-signature legality, notarization, signatory authority, revocation, and secure storage of executed agreements.


Need help? Contact support

be ready to get more
Join over 28 million airSlate SignNow users